APO Research
Talk to an analyst

APO RESEARCH · REPORT

Meningococcal Disease Treatment

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Meningococcal Disease Treatment Industry Growth and Trends Forecast to 2032

19 December 2025101 pages

Choose your research edition.

Industry ResearchMeningococcal Disease Treatment Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Meningococcal Disease Treatment Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Meningococcal Disease Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Meningococcal Disease Treatment Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Meningococcal Disease Treatment Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

According to APO Research, the global Meningococcal Disease Treatment market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Meningococcal Disease Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Meningococcal Disease Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Meningococcal Disease Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global companies in the Meningococcal Disease Treatment market include Walvax Biotechnology Co.,Ltd., Apeloa Pharmaceutical Co.,Ltd., Novartis, Merck Sharp & Dohme, Beijing Minhai Biological Technology Co.,Ltd., CanSino Biologics Inc., Shandong Jincheng Pharmaceutical Group Co.,ltd., Pfizer and Hebei Hejia Pharmaceutical Technology Group Co., Ltd, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Meningococcal Disease Treatment market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Meningococcal Disease Treatment market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Meningococcal Disease Treatment market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Meningococcal Disease Treatment.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global Meningococcal Disease Treatment market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Meningococcal Disease Treatment Market by Company

Walvax Biotechnology Co.,Ltd.

Apeloa Pharmaceutical Co.,Ltd.

Novartis

Merck Sharp & Dohme

Beijing Minhai Biological Technology Co.,Ltd.

CanSino Biologics Inc.

Shandong Jincheng Pharmaceutical Group Co.,ltd.

Pfizer

Hebei Hejia Pharmaceutical Technology Group Co., Ltd

GlaxoSmithKline

Chengdu Institute of Biology

Sanofi Pasteur

Meningococcal Disease Treatment Segment by Type

Antibiotics

Vaccines

Meningococcal Disease Treatment Segment by Application

Hospitals

Drugstores

Others

Meningococcal Disease Treatment Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Meningococcal Disease Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Meningococcal Disease Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Meningococcal Disease Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of Meningococcal Disease Treatment companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global Meningococcal Disease Treatment Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global Meningococcal Disease Treatment Market Size by Region (2021-2026) & (US$ Million) Table 3. Global Meningococcal Disease Treatment Market Share by Region (2021-2026) Table 4. Global Meningococcal Disease Treatment Market Size by Region (2027-2032) & (US$ Million) Table 5. Global Meningococcal Disease Treatment Market Share by Region (2027-2032) Table 6. Global Meningococcal Disease Treatment Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Meningococcal Disease Treatment Market Size by Type (2021-2026) & (US$ Million) Table 8. Global Meningococcal Disease Treatment Market Size Share by Type (2021-2026) Table 9. Global Meningococcal Disease Treatment Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global Meningococcal Disease Treatment Market Size Share Forecasted by Type (2027-2032) Table 11. North America Meningococcal Disease Treatment Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America Meningococcal Disease Treatment Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe Meningococcal Disease Treatment Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe Meningococcal Disease Treatment Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific Meningococcal Disease Treatment Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific Meningococcal Disease Treatment Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America Meningococcal Disease Treatment Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America Meningococcal Disease Treatment Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa Meningococcal Disease Treatment Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa Meningococcal Disease Treatment Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global Meningococcal Disease Treatment Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global Meningococcal Disease Treatment Market Size by Application (2021-2026) & (US$ Million) Table 23. Global Meningococcal Disease Treatment Market Size Share by Application (2021-2026) Table 24. Global Meningococcal Disease Treatment Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global Meningococcal Disease Treatment Market Size Share Forecasted by Application (2027-2032) Table 26. North America Meningococcal Disease Treatment Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America Meningococcal Disease Treatment Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe Meningococcal Disease Treatment Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe Meningococcal Disease Treatment Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific Meningococcal Disease Treatment Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific Meningococcal Disease Treatment Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America Meningococcal Disease Treatment Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America Meningococcal Disease Treatment Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa Meningococcal Disease Treatment Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa Meningococcal Disease Treatment Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. Meningococcal Disease Treatment Industry Trends Table 37. Meningococcal Disease Treatment Industry Drivers Table 38. Meningococcal Disease Treatment Industry Opportunities and Challenges Table 39. Meningococcal Disease Treatment Industry Restraints Table 40. Global Meningococcal Disease Treatment Revenue by Company (US$ Million) & (2021-2026) Table 41. Global Meningococcal Disease Treatment Revenue Market Share by Company (2021-2026) Table 42. Global Meningococcal Disease Treatment Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global Meningococcal Disease Treatment Key Company Headquarters & Area Served Table 44. Global Meningococcal Disease Treatment Company, Product Type & Application Table 45. Global Meningococcal Disease Treatment Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global Meningococcal Disease Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. Walvax Biotechnology Co.,Ltd. Company Information Table 49. Walvax Biotechnology Co.,Ltd. Business Overview Table 50. Walvax Biotechnology Co.,Ltd. Meningococcal Disease Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. Walvax Biotechnology Co.,Ltd. Meningococcal Disease Treatment Product Portfolio Table 52. Walvax Biotechnology Co.,Ltd. Recent Development Table 53. Apeloa Pharmaceutical Co.,Ltd. Company Information Table 54. Apeloa Pharmaceutical Co.,Ltd. Business Overview Table 55. Apeloa Pharmaceutical Co.,Ltd. Meningococcal Disease Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. Apeloa Pharmaceutical Co.,Ltd. Meningococcal Disease Treatment Product Portfolio Table 57. Apeloa Pharmaceutical Co.,Ltd. Recent Development Table 58. Novartis Company Information Table 59. Novartis Business Overview Table 60. Novartis Meningococcal Disease Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. Novartis Meningococcal Disease Treatment Product Portfolio Table 62. Novartis Recent Development Table 63. Merck Sharp & Dohme Company Information Table 64. Merck Sharp & Dohme Business Overview Table 65. Merck Sharp & Dohme Meningococcal Disease Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. Merck Sharp & Dohme Meningococcal Disease Treatment Product Portfolio Table 67. Merck Sharp & Dohme Recent Development Table 68. Beijing Minhai Biological Technology Co.,Ltd. Company Information Table 69. Beijing Minhai Biological Technology Co.,Ltd. Business Overview Table 70. Beijing Minhai Biological Technology Co.,Ltd. Meningococcal Disease Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. Beijing Minhai Biological Technology Co.,Ltd. Meningococcal Disease Treatment Product Portfolio Table 72. Beijing Minhai Biological Technology Co.,Ltd. Recent Development Table 73. CanSino Biologics Inc. Company Information Table 74. CanSino Biologics Inc. Business Overview Table 75. CanSino Biologics Inc. Meningococcal Disease Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. CanSino Biologics Inc. Meningococcal Disease Treatment Product Portfolio Table 77. CanSino Biologics Inc. Recent Development Table 78. Shandong Jincheng Pharmaceutical Group Co.,ltd. Company Information Table 79. Shandong Jincheng Pharmaceutical Group Co.,ltd. Business Overview Table 80. Shandong Jincheng Pharmaceutical Group Co.,ltd. Meningococcal Disease Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. Shandong Jincheng Pharmaceutical Group Co.,ltd. Meningococcal Disease Treatment Product Portfolio Table 82. Shandong Jincheng Pharmaceutical Group Co.,ltd. Recent Development Table 83. Pfizer Company Information Table 84. Pfizer Business Overview Table 85. Pfizer Meningococcal Disease Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. Pfizer Meningococcal Disease Treatment Product Portfolio Table 87. Pfizer Recent Development Table 88. Hebei Hejia Pharmaceutical Technology Group Co., Ltd Company Information Table 89. Hebei Hejia Pharmaceutical Technology Group Co., Ltd Business Overview Table 90. Hebei Hejia Pharmaceutical Technology Group Co., Ltd Meningococcal Disease Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 91. Hebei Hejia Pharmaceutical Technology Group Co., Ltd Meningococcal Disease Treatment Product Portfolio Table 92. Hebei Hejia Pharmaceutical Technology Group Co., Ltd Recent Development Table 93. GlaxoSmithKline Company Information Table 94. GlaxoSmithKline Business Overview Table 95. GlaxoSmithKline Meningococcal Disease Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 96. GlaxoSmithKline Meningococcal Disease Treatment Product Portfolio Table 97. GlaxoSmithKline Recent Development Table 98. Chengdu Institute of Biology Company Information Table 99. Chengdu Institute of Biology Business Overview Table 100. Chengdu Institute of Biology Meningococcal Disease Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 101. Chengdu Institute of Biology Meningococcal Disease Treatment Product Portfolio Table 102. Chengdu Institute of Biology Recent Development Table 103. Sanofi Pasteur Company Information Table 104. Sanofi Pasteur Business Overview Table 105. Sanofi Pasteur Meningococcal Disease Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 106. Sanofi Pasteur Meningococcal Disease Treatment Product Portfolio Table 107. Sanofi Pasteur Recent Development Table 108. North America Meningococcal Disease Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 109. North America Meningococcal Disease Treatment Market Size by Country (2021-2026) & (US$ Million) Table 110. North America Meningococcal Disease Treatment Market Share by Country (2021-2026) Table 111. North America Meningococcal Disease Treatment Market Size Forecast by Country (2027-2032) & (US$ Million) Table 112. North America Meningococcal Disease Treatment Market Share Forecast by Country (2027-2032) Table 113. Europe Meningococcal Disease Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 114. Europe Meningococcal Disease Treatment Market Size by Country (2021-2026) & (US$ Million) Table 115. Europe Meningococcal Disease Treatment Market Share by Country (2021-2026) Table 116. Europe Meningococcal Disease Treatment Market Size Forecast by Country (2027-2032) & (US$ Million) Table 117. Europe Meningococcal Disease Treatment Market Share Forecast by Country (2027-2032) Table 118. Asia-Pacific Meningococcal Disease Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 119. Asia-Pacific Meningococcal Disease Treatment Market Size by Country (2021-2026) & (US$ Million) Table 120. Asia-Pacific Meningococcal Disease Treatment Market Share by Country (2021-2026) Table 121. Asia-Pacific Meningococcal Disease Treatment Market Size Forecast by Country (2027-2032) & (US$ Million) Table 122. Asia-Pacific Meningococcal Disease Treatment Market Share Forecast by Country (2027-2032) Table 123. Latin America Meningococcal Disease Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 124. Latin America Meningococcal Disease Treatment Market Size by Country (2021-2026) & (US$ Million) Table 125. Latin America Meningococcal Disease Treatment Market Share by Country (2021-2026) Table 126. Latin America Meningococcal Disease Treatment Market Size Forecast by Country (2027-2032) & (US$ Million) Table 127. Latin America Meningococcal Disease Treatment Market Share Forecast by Country (2027-2032) Table 128. Middle East & Africa Meningococcal Disease Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 129. Middle East & Africa Meningococcal Disease Treatment Market Size by Country (2021-2026) & (US$ Million) Table 130. Middle East & Africa Meningococcal Disease Treatment Market Share by Country (2021-2026) Table 131. Middle East & Africa Meningococcal Disease Treatment Market Size Forecast by Country (2027-2032) & (US$ Million) Table 132. Middle East & Africa Meningococcal Disease Treatment Market Share Forecast by Country (2027-2032) Table 133. Research Programs/Design for This Report Table 134. Authors List of This Report Table 135. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. Meningococcal Disease Treatment Product Image Figure 3. Global Meningococcal Disease Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Meningococcal Disease Treatment Market Size (2021-2032) & (US$ Million) Figure 5. Global Meningococcal Disease Treatment Market Share by Region: 2025 VS 2032 Figure 6. Global Meningococcal Disease Treatment Market Share by Region (2021-2032) Figure 7. North America Meningococcal Disease Treatment Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe Meningococcal Disease Treatment Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific Meningococcal Disease Treatment Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America Meningococcal Disease Treatment Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa Meningococcal Disease Treatment Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. Antibiotics Image Figure 13. Global Antibiotics Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. Vaccines Image Figure 15. Global Vaccines Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Global Meningococcal Disease Treatment Market Size Overview by Type (2021-2032) & (US$ Million) Figure 17. Global Meningococcal Disease Treatment Market Share by Type 2025 VS 2032 Figure 18. North America Meningococcal Disease Treatment Market Size Share by Type (2021-2032) Figure 19. Europe Meningococcal Disease Treatment Market Size Share by Type (2021-2032) Figure 20. Asia-Pacific Meningococcal Disease Treatment Market Size Share by Type (2021-2032) Figure 21. Latin America Meningococcal Disease Treatment Market Size Share by Type (2021-2032) Figure 22. Middle East and Africa Meningococcal Disease Treatment Market Size Share by Type (2021-2032) Figure 23. Hospitals Image Figure 24. Global Hospitals Market Size YoY Growth (2021-2032) & (US$ Million) Figure 25. Drugstores Image Figure 26. Global Drugstores Market Size YoY Growth (2021-2032) & (US$ Million) Figure 27. Others Image Figure 28. Global Others Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. Global Meningococcal Disease Treatment Market Size Overview by Application (2021-2032) & (US$ Million) Figure 30. Global Meningococcal Disease Treatment Market Share by Application 2025 VS 2032 Figure 31. North America Meningococcal Disease Treatment Market Size Share by Application (2021-2032) Figure 32. Europe Meningococcal Disease Treatment Market Size Share by Application (2021-2032) Figure 33. Asia-Pacific Meningococcal Disease Treatment Market Size Share by Application (2021-2032) Figure 34. Latin America Meningococcal Disease Treatment Market Size Share by Application (2021-2032) Figure 35. Middle East and Africa Meningococcal Disease Treatment Market Size Share by Application (2021-2032) Figure 36. Global Top 5 and 10 Meningococcal Disease Treatment Players Market Share by Revenue in 2025 Figure 37. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 38. North America Meningococcal Disease Treatment Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 39. North America Meningococcal Disease Treatment Market Share by Country: 2021 VS 2025 VS 2032 Figure 40. North America Meningococcal Disease Treatment Market Share by Country (2021-2032) Figure 41. Europe Meningococcal Disease Treatment Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 42. Europe Meningococcal Disease Treatment Market Share by Country: 2021 VS 2025 VS 2032 Figure 43. Europe Meningococcal Disease Treatment Market Share by Country (2021-2032) Figure 44. Asia-Pacific Meningococcal Disease Treatment Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 45. Asia-Pacific Meningococcal Disease Treatment Market Share by Country: 2021 VS 2025 VS 2032 Figure 46. Asia-Pacific Meningococcal Disease Treatment Market Share by Country (2021-2032) Figure 47. Latin America Meningococcal Disease Treatment Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Latin America Meningococcal Disease Treatment Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Latin America Meningococcal Disease Treatment Market Share by Country (2021-2032) Figure 50. Middle East & Africa Meningococcal Disease Treatment Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 51. Middle East & Africa Meningococcal Disease Treatment Market Share by Country: 2021 VS 2025 VS 2032 Figure 52. Middle East & Africa Meningococcal Disease Treatment Market Share by Country (2021-2032) Figure 53. Years Considered Figure 54. Research Process Figure 55. Key Executives Interviewed

Scope & coverage.

Types
  • Antibiotics
  • Vaccines
Applications
  • Hospitals
  • Drugstores
  • Others
Companies covered
  • Walvax Biotechnology Co.,Ltd.
  • Apeloa Pharmaceutical Co.,Ltd.
  • Novartis
  • Merck Sharp & Dohme
  • Beijing Minhai Biological Technology Co.,Ltd.
  • CanSino Biologics Inc.
  • Shandong Jincheng Pharmaceutical Group Co.,ltd.
  • Pfizer
  • Hebei Hejia Pharmaceutical Technology Group Co., Ltd
  • GlaxoSmithKline
  • Chengdu Institute of Biology
  • Sanofi Pasteur

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global Meningococcal Disease Treatment Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global Meningococcal Disease Treatment Market Size by Region (2021-2032)
  5. 1.4.1 Global Meningococcal Disease Treatment Market Size by Region (2021-2026)
  6. 1.4.2 Global Meningococcal Disease Treatment Market Size by Region (2027-2032)
  7. 1.5 Key Regions Meningococcal Disease Treatment Market Size (2021-2032)
  8. 1.5.1 North America Meningococcal Disease Treatment Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe Meningococcal Disease Treatment Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific Meningococcal Disease Treatment Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America Meningococcal Disease Treatment Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa Meningococcal Disease Treatment Market Size Growth Rate (2021-2032)
2 Meningococcal Disease Treatment Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 Antibiotics
  3. 2.1.2 Vaccines
  4. 2.2 Global Meningococcal Disease Treatment Market Size by Type
  5. 2.2.1 Global Meningococcal Disease Treatment Market Size Overview by Type (2021-2032)
  6. 2.2.2 Global Meningococcal Disease Treatment Historic Market Size Review by Type (2021-2026)
  7. 2.2.3 Global Meningococcal Disease Treatment Market Size Forecasted by Type (2027-2032)
  8. 2.3 Global Meningococcal Disease Treatment Market Size by Regions
  9. 2.3.1 North America Meningococcal Disease Treatment Market Size Breakdown by Type (2021-2026)
  10. 2.3.2 Europe Meningococcal Disease Treatment Market Size Breakdown by Type (2021-2026)
  11. 2.3.3 Asia-Pacific Meningococcal Disease Treatment Market Size Breakdown by Type (2021-2026)
  12. 2.3.4 South America Meningococcal Disease Treatment Market Size Breakdown by Type (2021-2026)
  13. 2.3.5 Middle East and Africa Meningococcal Disease Treatment Market Size Breakdown by Type (2021-2026)
3 Meningococcal Disease Treatment Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Hospitals
  3. 3.1.2 Drugstores
  4. 3.1.3 Others
  5. 3.2 Global Meningococcal Disease Treatment Market Size by Application
  6. 3.2.1 Global Meningococcal Disease Treatment Market Size Overview by Application (2021-2032)
  7. 3.2.2 Global Meningococcal Disease Treatment Historic Market Size Review by Application (2021-2026)
  8. 3.2.3 Global Meningococcal Disease Treatment Market Size Forecasted by Application (2027-2032)
  9. 3.3 Global Meningococcal Disease Treatment Market Size by Regions
  10. 3.3.1 North America Meningococcal Disease Treatment Market Size Breakdown by Application (2021-2026)
  11. 3.3.2 Europe Meningococcal Disease Treatment Market Size Breakdown by Application (2021-2026)
  12. 3.3.3 Asia-Pacific Meningococcal Disease Treatment Market Size Breakdown by Application (2021-2026)
  13. 3.3.4 South America Meningococcal Disease Treatment Market Size Breakdown by Application (2021-2026)
  14. 3.3.5 Middle East and Africa Meningococcal Disease Treatment Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 Meningococcal Disease Treatment Industry Trends
  2. 4.2 Meningococcal Disease Treatment Industry Drivers
  3. 4.3 Meningococcal Disease Treatment Industry Opportunities and Challenges
  4. 4.4 Meningococcal Disease Treatment Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by Meningococcal Disease Treatment Revenue (2021-2026)
  2. 5.2 Global Meningococcal Disease Treatment Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global Meningococcal Disease Treatment Key Company Headquarters & Area Served
  4. 5.4 Global Meningococcal Disease Treatment Company, Product Type & Application
  5. 5.5 Global Meningococcal Disease Treatment Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global Meningococcal Disease Treatment Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 Meningococcal Disease Treatment Players Market Share by Revenue in 2025
  9. 5.6.3 2025 Meningococcal Disease Treatment Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 Walvax Biotechnology Co.,Ltd.
  2. 6.1.1 Walvax Biotechnology Co.,Ltd. Company Information
  3. 6.1.2 Walvax Biotechnology Co.,Ltd. Business Overview
  4. 6.1.3 Walvax Biotechnology Co.,Ltd. Meningococcal Disease Treatment Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 Walvax Biotechnology Co.,Ltd. Meningococcal Disease Treatment Product Portfolio
  6. 6.1.5 Walvax Biotechnology Co.,Ltd. Recent Developments
  7. 6.2 Apeloa Pharmaceutical Co.,Ltd.
  8. 6.2.1 Apeloa Pharmaceutical Co.,Ltd. Company Information
  9. 6.2.2 Apeloa Pharmaceutical Co.,Ltd. Business Overview
  10. 6.2.3 Apeloa Pharmaceutical Co.,Ltd. Meningococcal Disease Treatment Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 Apeloa Pharmaceutical Co.,Ltd. Meningococcal Disease Treatment Product Portfolio
  12. 6.2.5 Apeloa Pharmaceutical Co.,Ltd. Recent Developments
  13. 6.3 Novartis
  14. 6.3.1 Novartis Company Information
  15. 6.3.2 Novartis Business Overview
  16. 6.3.3 Novartis Meningococcal Disease Treatment Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 Novartis Meningococcal Disease Treatment Product Portfolio
  18. 6.3.5 Novartis Recent Developments
  19. 6.4 Merck Sharp & Dohme
  20. 6.4.1 Merck Sharp & Dohme Company Information
  21. 6.4.2 Merck Sharp & Dohme Business Overview
  22. 6.4.3 Merck Sharp & Dohme Meningococcal Disease Treatment Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 Merck Sharp & Dohme Meningococcal Disease Treatment Product Portfolio
  24. 6.4.5 Merck Sharp & Dohme Recent Developments
  25. 6.5 Beijing Minhai Biological Technology Co.,Ltd.
  26. 6.5.1 Beijing Minhai Biological Technology Co.,Ltd. Company Information
  27. 6.5.2 Beijing Minhai Biological Technology Co.,Ltd. Business Overview
  28. 6.5.3 Beijing Minhai Biological Technology Co.,Ltd. Meningococcal Disease Treatment Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 Beijing Minhai Biological Technology Co.,Ltd. Meningococcal Disease Treatment Product Portfolio
  30. 6.5.5 Beijing Minhai Biological Technology Co.,Ltd. Recent Developments
  31. 6.6 CanSino Biologics Inc.
  32. 6.6.1 CanSino Biologics Inc. Company Information
  33. 6.6.2 CanSino Biologics Inc. Business Overview
  34. 6.6.3 CanSino Biologics Inc. Meningococcal Disease Treatment Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 CanSino Biologics Inc. Meningococcal Disease Treatment Product Portfolio
  36. 6.6.5 CanSino Biologics Inc. Recent Developments
  37. 6.7 Shandong Jincheng Pharmaceutical Group Co.,ltd.
  38. 6.7.1 Shandong Jincheng Pharmaceutical Group Co.,ltd. Company Information
  39. 6.7.2 Shandong Jincheng Pharmaceutical Group Co.,ltd. Business Overview
  40. 6.7.3 Shandong Jincheng Pharmaceutical Group Co.,ltd. Meningococcal Disease Treatment Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 Shandong Jincheng Pharmaceutical Group Co.,ltd. Meningococcal Disease Treatment Product Portfolio
  42. 6.7.5 Shandong Jincheng Pharmaceutical Group Co.,ltd. Recent Developments
  43. 6.8 Pfizer
  44. 6.8.1 Pfizer Company Information
  45. 6.8.2 Pfizer Business Overview
  46. 6.8.3 Pfizer Meningococcal Disease Treatment Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 Pfizer Meningococcal Disease Treatment Product Portfolio
  48. 6.8.5 Pfizer Recent Developments
  49. 6.9 Hebei Hejia Pharmaceutical Technology Group Co., Ltd
  50. 6.9.1 Hebei Hejia Pharmaceutical Technology Group Co., Ltd Company Information
  51. 6.9.2 Hebei Hejia Pharmaceutical Technology Group Co., Ltd Business Overview
  52. 6.9.3 Hebei Hejia Pharmaceutical Technology Group Co., Ltd Meningococcal Disease Treatment Revenue, Global Share and Gross Margin (2021-2026)
  53. 6.9.4 Hebei Hejia Pharmaceutical Technology Group Co., Ltd Meningococcal Disease Treatment Product Portfolio
  54. 6.9.5 Hebei Hejia Pharmaceutical Technology Group Co., Ltd Recent Developments
  55. 6.10 GlaxoSmithKline
  56. 6.10.1 GlaxoSmithKline Company Information
  57. 6.10.2 GlaxoSmithKline Business Overview
  58. 6.10.3 GlaxoSmithKline Meningococcal Disease Treatment Revenue, Global Share and Gross Margin (2021-2026)
  59. 6.10.4 GlaxoSmithKline Meningococcal Disease Treatment Product Portfolio
  60. 6.10.5 GlaxoSmithKline Recent Developments
  61. 6.11 Chengdu Institute of Biology
  62. 6.11.1 Chengdu Institute of Biology Company Information
  63. 6.11.2 Chengdu Institute of Biology Business Overview
  64. 6.11.3 Chengdu Institute of Biology Meningococcal Disease Treatment Revenue, Global Share and Gross Margin (2021-2026)
  65. 6.11.4 Chengdu Institute of Biology Meningococcal Disease Treatment Product Portfolio
  66. 6.11.5 Chengdu Institute of Biology Recent Developments
  67. 6.12 Sanofi Pasteur
  68. 6.12.1 Sanofi Pasteur Company Information
  69. 6.12.2 Sanofi Pasteur Business Overview
  70. 6.12.3 Sanofi Pasteur Meningococcal Disease Treatment Revenue, Global Share and Gross Margin (2021-2026)
  71. 6.12.4 Sanofi Pasteur Meningococcal Disease Treatment Product Portfolio
  72. 6.12.5 Sanofi Pasteur Recent Developments
7 North America
  1. 7.1 North America Meningococcal Disease Treatment Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America Meningococcal Disease Treatment Market Size by Country (2021-2026)
  3. 7.3 North America Meningococcal Disease Treatment Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe Meningococcal Disease Treatment Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe Meningococcal Disease Treatment Market Size by Country (2021-2026)
  3. 8.3 Europe Meningococcal Disease Treatment Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific Meningococcal Disease Treatment Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific Meningococcal Disease Treatment Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific Meningococcal Disease Treatment Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America Meningococcal Disease Treatment Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America Meningococcal Disease Treatment Market Size by Country (2021-2026)
  3. 10.3 South America Meningococcal Disease Treatment Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa Meningococcal Disease Treatment Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa Meningococcal Disease Treatment Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa Meningococcal Disease Treatment Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst